Cite
HARVARD Citation
Onishi, M. et al. (n.d.). Brentuximab vedotin administered to platinum‐refractory, transplant‐naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. Hematological oncology. 33 (4), pp. 187-191. [Online].